Pluri Extends EIB Loan Talks Beyond July 3 Deadline Without Enforcement Action
PLUR is trading near its 52-week low of $1.56 (7.7% above the low) on elevated volume (3.4× avg).
Summary
Pluri's EIB loan discussions have extended past the July 3 deadline without enforcement action, with the EIB indicating constructive progress. This provides temporary relief amid an acute liquidity crisis and Nasdaq delisting threat.
Key Events · Legal and Risk Events · PLUR
-
EIB Loan Talks Extended
Discussions with the European Investment Bank on the €20 million loan have continued past the July 3, 2026 deadline without enforcement action, and the EIB indicates constructive progress.
-
No Enforcement Action
The EIB has not exercised remedies under the finance agreement, providing Pluri with additional time to negotiate a resolution.
-
Liquidity Crisis Context
Pluri faces an acute liquidity crisis with less than three months of cash runway and a $27.4 million loan obligation, making this extension critical for survival.
-
Nasdaq Delisting Threat
The company received a Nasdaq delisting notice on July 13, 2026, after its market value fell below the $35 million minimum, adding urgency to resolving the EIB loan.
Analysis · PLUR · Life Sciences
Pluri's €20 million EIB loan matured on June 1, 2026, and the company has been in a liquidity crisis with less than three months of cash. The EIB had previously agreed not to take enforcement action until July 3, 2026. This filing reveals that discussions have continued past that deadline without enforcement, and the EIB has indicated constructive progress, though no resolution is guaranteed. This buys Pluri critical time to avoid a default that could trigger cross-defaults and accelerate its financial distress, especially given the recent Nasdaq delisting notice.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLUR was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.1M. The 52-week trading range was $1.56 to $5.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.